
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a leading medical device company that specializes in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management. The company's innovative product line and strong sales force make it well-positioned for growth in the coming years. Despite its current valuation, which may be seen as high by some, the company's strong financial performance and focus on product development and clinical trials make it a solid investment for long-term investors. AtriCure's potential in multiple areas of surgical treatment, along with its plans for continued profitability improvement, make it an attractive investment opportunity.
Bears say
AtriCure is facing significant headwinds in its minimally invasive ablation platform, with declines in US revenue and only moderate growth in international revenue. The recent launch of MDT's Pendigo device may further impact AtriCure's left atrial appendage management growth. Additionally, AtriCure faces stiff competition from MDT's broad cardiac surgery business compared to EW's limited offerings. Despite high revenue growth, AtriCure's struggles and uncertain path to profitability lead to a negative outlook.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares